Skip to content

Resistance Exercise in Hemodialysis Patients

The Impact of Resistance Exercise on Symptom Burden in Older Patients Undergoing Maintenance Hemodialysis

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06604221
Acronym
REHDP
Enrollment
54
Registered
2024-09-19
Start date
2024-10-03
Completion date
2025-03-03
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis

Keywords

resistance exercise, hemodialysis, older people

Brief summary

The goal of this clinical trial is to learn if an intradialytic resistance exercise intervention works to reduce the symptom burden in older maintenance hemodialysis patients. It will also learn about safety of the intradialytic resistance exercise intervention program. The main questions it aims to answer are: 1. Does intradialytic resistance exercise effectively improve the number, frequency, and severity of symptoms in older patients? 2. What adverse events may occur among older dialysis patients during exercise? Researchers will compare older dialysis patients who undergo the intradialytic resistance exercise intervention with those receiving standard care to observe whether resistance exercise can improve symptom burden. Participants will: 1. Take an intradialytic resistance exercise intervention program developed through joint decision-making by rehabilitation experts, dialysis center physicians, nurses, and patients, conducted three times a week for 20 minutes each session, over a duration of three months. 2. Visit the hospital a monthly for texts and examinations. 3. Keep a diary of the types and frequency of adverse events during and after the exercise sessions.

Interventions

The exercise prescription, developed through expert meetings and integrated review summaries, consists of 27 items including: participant preparation, team preparation, exercise prescription FITT-VP, process monitoring, discontinuation criteria, termination criteria, recovery methods, outcome measures, and special considerations.

BEHAVIORALRoutine care

1.Pre-dialysis Assessment: 1. Vital Signs: Monitor blood pressure, heart rate, temperature. 2. Access Care: Check the vascular access site for signs of infection and patency. 2.During Dialysis: (1)Monitoring: Continuous vital signs and machine settings monitoring. (2)Fluid Management: Control fluid removal based on pre-dialysis weight. 3.Post-dialysis Care: 1. Observation: Monitor for complications like hypotension, cramps, or bleeding. 2. Weight Check: Weigh post-dialysis to verify fluid removal. 4.Education and Support: (1)Diet: Educate on dietary restrictions (potassium, phosphorus, fluids). (2)Medications: Advise on medication adjustments. 5.Psychosocial Support: (1)Provide emotional support and counseling.

Sponsors

Shengjing Hospital
CollaboratorOTHER
Teng Zeng
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Age 60 years and above Stable on dialysis for ≥3 months Able to walk independently, no physical disability, and muscle strength ≥ Grade III Capable of understanding and complying with the requirements of this study Voluntarily signed an informed consent form

Exclusion criteria

Severe cardiovascular, cerebrovascular, respiratory, or neurological diseases, or other conditions that impair physical ability to exercise Serious infections, bleeding, trauma, or other conditions affecting physical status within the last 3 months Severe mental disorders or cognitive impairments Abnormal blood pressure (pre-dialysis systolic pressure ≥180mmHg, diastolic pressure ≥100mmHg) Hemoglobin (Hb) < 90g/L, Albumin (Alb) ≤ 32g/L Participation in other exercise or pharmacological interventions in the past 6 months

Design outcomes

Primary

MeasureTime frameDescription
Dialysis Symptom IndexFrom enrollment to the end of treatment at 12 weeksKidney failure-related symptoms were assessed every month using the dialysis symptom index (DSI), a previously validated questionnaire Through this questionnaire, patients indicated the presence of 30 symptoms in the past month, resulting in a total sum score for symptom number ranging from 0 to 30. Additionally, for each symptom present, patients rated symptom burden on a five-point Likert scale, ranging from one for not at all to five for very much burdensome. Absent symptoms were assigned a score of zero, resulting in an overall symptom burden score ranging from zero to 150, with higher scores indicating larger burden.

Secondary

MeasureTime frameDescription
30 Seconds Sit To Stand TestFrom enrollment to the end of treatment at 12 weeksA chair with a hard seat whose floor-to-seat height was 48 cm was stabilized by placing it against a wall. After a researcher explained the requirements and precautions to the participant, the participant was asked to sit with his or her feet exactly flat on the ground and his or her upper limbs folded across his or her chest and then to stand up all the way and sit down again without using his or her arms. And the participant was asked to repeat as many of the sit-to-stand actions as possible in 30 seconds, and the maximum number completed was recorded. Higher scores mean a better outcome.
Short Physical Performance BatteryFrom enrollment to the end of treatment at 12 weeks(SPPB) which consists of 3 timed components: 1) a 4-meter usual pace walk, 2) a five-repetition chair stand without using one's arms, and 3) a progressive test of standing balance. Times from each component were scored from 0-4, with higher scores corresponding to better performance.
Number of participants with abnormal laboratory tests resultsFrom enrollment to the end of treatment at 12 weeksblood urea, blood creatinine, dialysis adequacy (Kt/V), hemoglobin, neutrophil-to-lymphocyte ratio, serum albumin, standardized protein catabolic rate, C-reactive protein, inflammatory factors

Contacts

Primary ContactZeng Teng, Graduate Student
tengzeng412@gmail.com+86 13096390520

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026